Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of -22.22% and -11.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Harmony Biosciences (HRMY) Soars 10.0%: Is Further Upside Left in the Stock?
Harmony Biosciences (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
Syndax Pharmaceuticals (SNDX) Is Up 8.20% in One Week: What You Should Know
Does Syndax Pharmaceuticals (SNDX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet
The consensus price target hints at a 70.4% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?
Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates...
Yahoo! Finance: News
Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential
Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential...
Yahoo! Finance: News
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% Following Analyst Upgrade
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% on Analyst Upgrade...
MarketBeat
HC Wainwright Has Optimistic Outlook of SNDX FY2030 Earnings
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Equities researchers at HC Wainwright increased their FY2030 EPS estimates for Syndax Pharmaceuticals in a note issued to investors on Friday, May 1st. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of $3...
MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 7.1% - Time to Sell?
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 7.1% - Should You Sell...
MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $37.00
Barclays raised their price target on Syndax Pharmaceuticals from $35.00 to $37.00 and gave the stock an "overweight" rating in a research note on Friday...
MarketBeat

Advertisement|Remove ads.